Young Women with Breast Cancer in Resource-Limited Settings: What We Know and What We Need to Do Better

References

• SungH, FerlayJ, SiegelRL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.2166033538338
   PubMed Web of Science ®Google Scholar
• Gálvez-HernándezCL, González-RobledoMC, Barragán-CarrilloR, Villarreal-GarzaC. Special needs of young women with breast cancer in limited resource settings. Rev Invest Clin. 2017;69(4):210–222.28776606
   PubMedGoogle Scholar
• Villarreal-GarzaC, AguilaC, Magallanes-HoyosMC, et al. Breast cancer in young women in Latin America: an unmet, growing burden. Oncologist. 2013;18(Suppl):26–34. doi:10.1634/theoncologist.18-S2-2624334479
   PubMedGoogle Scholar
• PorterP. “Westernizing” women’s risks? Breast cancer in lower-income countries. N Engl J Med. 2008;358(3):213–216. doi:10.1056/NEJMp070830718199859
   PubMed Web of Science ®Google Scholar
• Paluch-ShimonS, PaganiO, PartridgeAH, et al. Second international consensus guidelines for breast cancer in young women (BCY2). Breast. 2016;26:87–99. doi:10.1016/j.breast.2015.12.01027017247
   PubMed Web of Science ®Google Scholar
• AzimHAJ, PartridgeAH. Biology of breast cancer in young women. Breast Cancer Res. 2014;16(4):427. doi:10.1186/s13058-014-0427-525436920
   PubMed Web of Science ®Google Scholar
• HarirchiI, KarbakhshM, KashefiA, MomtahenAJ. Breast cancer in Iran: results of a multi-center study. Asian Pac J Cancer Prev. 2004;5(1):24–27.15075000
   PubMedGoogle Scholar
• AdesunkanmiARK, LawalOO, AdelusolaKA, DurosimiMA. The severity, outcome and challenges of breast cancer in Nigeria. Breast. 2006;15(3):399–409. doi:10.1016/j.breast.2005.06.00816085418
   PubMed Web of Science ®Google Scholar
• Villarreal-GarzaC, PlatasA, MiajaM, et al. Young women with breast cancer in Mexico: results of the pilot phase of the Joven & Fuerte prospective cohort. JCO Glob Oncol. 2020;6:395–406. doi:10.1200/JGO.19.0026432142405
   PubMedGoogle Scholar
• DeshmukhSP, ManeAD, ZadeBP, SaneSP. Breast cancer in young women in India. Ann Oncol. 2012;23:ix101. doi:10.1016/S0923-7534(20)32826-X
   Google Scholar
• OrlandiniLF, AntonioMVDN, EspreaficoCRJ, et al. Epidemiological analyses reveal a high incidence of breast cancer in young women in Brazil. JCO Glob Oncol. 2021;7:81–88. doi:10.1200/GO.20.0044033434069
   PubMedGoogle Scholar
• Villarreal-GarzaC, Martinez-CannonBA, PlatasA, Ramos-EliasP. Specialized programs to support young women with breast cancer. Curr Opin Support Palliat Care. 2015;9(3):308–316. doi:10.1097/SPC.000000000000015526125308
   PubMed Web of Science ®Google Scholar
• PartridgeAH, GelberS, PeppercornJ, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004;22(20):4174–4183. doi:10.1200/JCO.2004.01.15915483028
   PubMed Web of Science ®Google Scholar
• FobairP, StewartSL, ChangS, D’OnofrioC, BanksPJ, BloomJR. Body image and sexual problems in young women with breast cancer. Psychooncology. 2006;15(7):579–594. doi:10.1002/pon.99116287197
   PubMed Web of Science ®Google Scholar
• TakahashiM. Psychosocial distress among young breast cancer survivors: implications for healthcare providers. Breast Cancer. 2014;21(6):664–669.24318377
   PubMed Web of Science ®Google Scholar
• BasroS, ApffelstaedtJP. Breast cancer in young women in a limited-resource environment. World J Surg. 2010;34(7):1427–1433. doi:10.1007/s00268-009-0299-519997919
   PubMed Web of Science ®Google Scholar
• The World Bank. The world by income and region; 2021. Available from:https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups. Accessed September22, 2021.
   Google Scholar
• Villarreal-GarzaC, Bargallo-RochaJE, Soto-perez-de-celisE, et al. Real-world outcomes in young women with breast cancer treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2016;157(2):385–394. doi:10.1007/s10549-016-3811-227189008
   PubMed Web of Science ®Google Scholar
• Villarreal-GarzaC, MoharA, Bargallo-RochaJE, et al. Molecular subtypes and prognosis in young Mexican women with breast cancer. Clin Breast Cancer. 2017;17(3):e95–e102. doi:10.1016/j.clbc.2016.11.00728065398
   PubMedGoogle Scholar
• AhnSH, SonBH, KimSW, et al. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea–a report from the Korean breast cancer society. J Clin Oncol. 2007;25(17):2360–2368. doi:10.1200/JCO.2006.10.375417515570
   PubMed Web of Science ®Google Scholar
• AzimHA, MichielsS, BedardPL, et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res. 2012;18(5):1341–1351. doi:10.1158/1078-0432.CCR-11-259922261811
   PubMed Web of Science ®Google Scholar
• Villarreal-GarzaC, Reynoso-NoveronN, Arce-SalinasC, et al. Abstract P6-08-55: high triple-negative breast cancer prevalence and poor outcome of hormone receptor positive breast cancer among young Mexican women. Cancer Res. 2015;75(9Supplement):P6-08-55-P6-08-55. doi:10.1158/1538-7445.SABCS14-P6-08-55
   Web of Science ®Google Scholar
• TangL-C, JinX, YangH-Y, et al. Luminal B subtype: a key factor for the worse prognosis of young breast cancer patients in China. BMC Cancer. 2015;15:201. doi:10.1186/s12885-015-1207-z25885213
   PubMed Web of Science ®Google Scholar
• HershmanDL, KushiLH, ShaoT, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8769 early-stage breast cancer patients. J Clin Oncol. 2010;28(27):4120–4128. doi:10.1200/JCO.2009.25.965520585090
   PubMed Web of Science ®Google Scholar
• BarronTI, ConnollyRM, BennettK, FeelyJ, KennedyMJ. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer. 2007;109(5):832–839. doi:10.1002/cncr.2248517243168
   PubMed Web of Science ®Google Scholar
• BursteinHJ, TeminS, AndersonH, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255–2269. doi:10.1200/JCO.2013.54.225824868023
   PubMed Web of Science ®Google Scholar
• Paluch-ShimonS, CardosoF, PartridgeAH, et al. ESO-ESMO 4th international consensus guidelines for Breast Cancer in Young Women (BCY4). Ann Oncol. 2020;31(6):674–696. doi:10.1016/j.annonc.2020.03.28432199930
   PubMed Web of Science ®Google Scholar
• CluzeC, ReyD, HuiartL, et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol. 2012;23(4):882–890. doi:10.1093/annonc/mdr33021788360
   PubMed Web of Science ®Google Scholar
• HuiartL, BouhnikAD, ReyD, et al. Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed?Eur J Cancer. 2012;48(13):1939–1946. doi:10.1016/j.ejca.2012.03.00422464016
   PubMed Web of Science ®Google Scholar
• WassermannJ, GelberSI, RosenbergSM, et al. Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer. Cancer. 2019;125(18):3266–3274. doi:10.1002/cncr.3219231120571
   PubMed Web of Science ®Google Scholar
• PistilliB, PaciA, FerreiraAR, et al. Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk. J Clin Oncol. 2020;38(24):2762–2772. doi:10.1200/JCO.19.0175832568632
   PubMed Web of Science ®Google Scholar
• Martinez-CannonBA, Castro-SanchezA, Barragan-CarrilloR, et al. Adherence to adjuvant tamoxifen in Mexican young women with breast cancer. Patient Prefer Adherence. 2021;15:1039–1049. doi:10.2147/PPA.S29674734040357
   PubMed Web of Science ®Google Scholar
• Villarreal-GarzaC, Mesa-ChavezF, FerrignoAS, et al. Adjuvant endocrine therapy for premenopausal women with breast cancer: patient adherence and physician prescribing practices in Mexico. Breast. 2021;59:8–15. doi:10.1016/j.breast.2021.05.01334116366
   PubMed Web of Science ®Google Scholar
• LlarenaNC, EstevezSL, TuckerSL, JerussJS. Impact of fertility concerns on tamoxifen initiation and persistence. J Natl Cancer Inst. 2015;107(10):djv202. doi:10.1093/jnci/djv202
   Google Scholar
• PartridgeAH, NimanSM, RuggeriM, et al. Who are the women who enrolled in the POSITIVE trial: a global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. Breast. 2021;59:327–338. doi:10.1016/j.breast.2021.07.02134390999
   PubMed Web of Science ®Google Scholar
• SellaT, PoorvuPD, RuddyKJ, et al. Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors. Cancer. 2021;127(16):2888–2894. doi:10.1002/cncr.3359633886123
   PubMed Web of Science ®Google Scholar
• McCowanC, ShearerJ, DonnanPT, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer. 2008;99(11):1763–1768. doi:10.1038/sj.bjc.660475818985046
   PubMed Web of Science ®Google Scholar
• LambertiniM, PeccatoriFA, DemeestereI, et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO clinical practice guidelines†. Ann Oncol. 2020;31(12):1664–1678. doi:10.1016/j.annonc.2020.09.00632976936
   PubMed Web of Science ®Google Scholar
• LambertiniM, GoldratO, Barragan-CarrilloR, VlgliettiG, DemeestereI, Villarreal-GarzaC. Viable options for fertility preservation in breast cancer patients: a focus on Latin America. Rev Invest Clin. 2017;69(2):103–113. doi:10.24875/RIC.1700217928453508
   PubMedGoogle Scholar
• Villarreal-GarzaC, Martinez-CannonBA, PlatasA, et al. Fertility concerns among breast cancer patients in Mexico. Breast. 2017;33:71–75. doi:10.1016/j.breast.2017.02.01028284061
   PubMed Web of Science ®Google Scholar
• Villarreal-GarzaC, Martinez-CannonBA, Barragan-CarrilloR, et al. Physicians’ attitudes, knowledge, and perceived barriers toward fertility preservation in young breast cancer patients in a developing country. Rev Invest Clin. 2020;73(3):347–353.
   Google Scholar
• KimJ, KimSK, HwangKJ, KimSH. Fertility preservation during cancer treatment: the Korean society for fertility preservation clinical guidelines. Clin Exp Reprod Med. 2017;44(4):171. doi:10.5653/cerm.2017.44.4.17129376012
   PubMedGoogle Scholar
• DyerKE, QuinnGP. Cancer and fertility preservation in Puerto Rico: a qualitative study of healthcare provider perceptions. Support Care Cancer. 2016;24(8):3353–3360. doi:10.1007/s00520-016-3166-626980331
   PubMed Web of Science ®Google Scholar
• KhanSZ, GarzaCV, SirohiB, et al. 8P Knowledge, practice and attitudes of physicians in low- and middle-income countries (LMIC) on fertility and pregnancy-related issues in young breast cancer patients. Ann Oncol. 2020;31:S1245. doi:10.1016/j.annonc.2020.10.028
   Web of Science ®Google Scholar
• PanagiotopoulouN, GhumanN, SandherR, HerbertM, StewartJA. Barriers and facilitators towards fertility preservation care for cancer patients: a meta-synthesis. Eur J Cancer Care. 2018;27(1):e12428. doi:10.1111/ecc.12428
   Web of Science ®Google Scholar
• PintoJA, PinillosL, Villarreal-GarzaC, et al. Barriers in Latin America for the management of locally advanced breast cancer. Ecancermedicalscience. 2019;13:897. doi:10.3332/ecancer.2019.89730792814
   PubMed Web of Science ®Google Scholar
• SalamaM, LarondaMM, LauraER, et al. Installing oncofertility programs for common cancers in optimum resource settings (Repro-Can-OPEN Study Part II): a committee opinion. J Assist Reprod Genet. 2021;38(1):163–176. doi:10.1007/s10815-020-02012-033452592
   PubMed Web of Science ®Google Scholar
• Villarreal-GarzaC, Mesa-ChavezF, Plata de la MoraA, et al. Prospective Study of fertility preservation in young women with breast cancer in Mexico. J Natl Compr Canc Netw. 2021:1–8. doi:10.6004/jnccn.2020.7692
   Google Scholar
• GuthU, HuangDJ, BitzerJ, MoffatR. Unintended pregnancy during the first year after breast cancer diagnosis. Eur J Contracept Reprod Health Care. 2016;21(4):290–294. doi:10.1080/13625187.2016.118067827227578
   PubMed Web of Science ®Google Scholar
• DurraniS, AkbarS, HeenaH. Breast cancer during pregnancy. Cureus. 2018;10(7):e2941. doi:10.7759/cureus.294130202672
   PubMed Web of Science ®Google Scholar
• MaslowB-SL, MorseCB, SchanneA, LorenA, DomchekSM, GraciaCR. Contraceptive use and the role of contraceptive counseling in reproductive-aged women with cancer. Contraception. 2014;90(1):79–85. doi:10.1016/j.contraception.2014.03.00224792148
   PubMed Web of Science ®Google Scholar
• JohansenSL, LermaK, ShawKA. Contraceptive counseling in reproductive-aged women treated for breast cancer at a tertiary care institution: a retrospective analysis. Contraception. 2017;96(4):248–253. doi:10.1016/j.contraception.2017.06.00428645785
   PubMed Web of Science ®Google Scholar
• Cook-AndersenH, KomrokianS, DeMicheleA, SuHI. Breast cancer patients have lower rates of contraception use. Fertil Steril. 2011;96(3):S201–S202. doi:10.1016/j.fertnstert.2011.07.781
   Web of Science ®Google Scholar
• KaraözB, AksuH, KüçükM. A qualitative study of the information needs of premenopausal women with breast cancer in terms of contraception, sexuality, early menopause, and fertility. Int J Gynaecol Obstet. 2010;109(2):118–120. doi:10.1016/j.ijgo.2009.11.02720152978
   PubMed Web of Science ®Google Scholar
• Castro-SanchezA, Martinez-CannonBA, PlatasA, et al. Suboptimal use of effective contraceptive methods in young Mexican women with breast cancer. J Glob Oncol. 2018;4:1–7. doi:10.1200/JGO.18.00064
   PubMed Web of Science ®Google Scholar
• HarriesJ, ConstantD, CairncrossL, MoodleyJ. Contraceptive needs and fertility intentions of women with breast cancer in Cape Town, South Africa: a qualitative study. BMC Women's Health. 2020;20(1):224. doi:10.1186/s12905-020-01094-333023554
   PubMed Web of Science ®Google Scholar
• MalekiM, MardaniA, GhafourifardM, VaismoradiM. Qualitative exploration of sexual life among breast cancer survivors at reproductive age. BMC Women's Health. 2021;21(1):56. doi:10.1186/s12905-021-01212-933563267
   PubMed Web of Science ®Google Scholar
• GilbertE, UssherJM, PerzJ. Sexuality after breast cancer: a review. Maturitas. 2010;66(4):397–407. doi:10.1016/j.maturitas.2010.03.02720439140
   PubMed Web of Science ®Google Scholar
• GhizzaniA, BruniS, LuisiS. The sex life of women surviving breast cancer. Gynecol Endocrinol. 2018;34(10):821–825. doi:10.1080/09513590.2018.146740129703097
   PubMed Web of Science ®Google Scholar
• UssherJM, PerzJ, GilbertE. Information needs associated with changes to sexual well-being after breast cancer. J Adv Nurs. 2013;69(2):327–337. doi:10.1111/j.1365-2648.2012.06010.x22500731
   PubMed Web of Science ®Google Scholar
• OlasehindeO, ArijeO, WuraolaFO, et al. Life without a breast: exploring the experiences of young Nigerian women after mastectomy for breast cancer. J Glob Oncol. 2019;5:1–6. doi:10.1200/JGO.18.00248
   Web of Science ®Google Scholar
• Villarreal-GarzaCM, PlatasA, Castro-SanchezA, et al. Sexual function and satisfaction in Mexican young women undergoing breast cancer treatment. J Clin Oncol. 2017;35(15_suppl):e21714–e21714. doi:10.1200/JCO.2017.35.15_suppl.e21714
   Web of Science ®Google Scholar
• FouladiN, FeiziI, NadermohammadiM, MehraraE, AdldoostiR, AlimohammadiS. The predictors of sexual satisfaction among Iranian women with breast cancer. Asian Pac J Cancer Prev. 2021;22(2):391–396. doi:10.31557/APJCP.2021.22.2.39133639652
   PubMedGoogle Scholar
• ArmstrongN, RyderS, ForbesC, RossJ, QuekRG. A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol. 2019;11:543–561. doi:10.2147/CLEP.S20694931372057
   PubMed Web of Science ®Google Scholar
• RosenbergSM, RuddyKJ, TamimiRM, et al. BRCA1 and BRCA2 mutation testing in young women with breast cancer. JAMA Oncol. 2016;2(6):730. doi:10.1001/jamaoncol.2015.594126867710
   PubMed Web of Science ®Google Scholar
• Villarreal-GarzaC, WeitzelJN, LlacuachaquiM, et al. The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer. Breast Cancer Res Treat. 2015;150(2):389–394. doi:10.1007/s10549-015-3312-825716084
   PubMed Web of Science ®Google Scholar
• DalyMB, PalT, BerryMP, et al. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(1):77–102. doi:10.6004/jnccn.2021.000133406487
   PubMed Web of Science ®Google Scholar
• LittonJK, RugoHS, EttlJ, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753–763. doi:10.1056/NEJMoa180290530110579
   PubMed Web of Science ®Google Scholar
• RobsonME, TungN, ConteP, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30(4):558–566. doi:10.1093/annonc/mdz01230689707
   PubMed Web of Science ®Google Scholar
• TuttANJ, GarberJE, KaufmanB, et al. Adjuvant olaparib for patients with BRCA1 - or BRCA2 -mutated breast cancer. N Engl J Med. 2021;384(25):2394–2405. doi:10.1056/NEJMoa210521534081848
   PubMed Web of Science ®Google Scholar
• Chavarri-GuerraY, BlazerKR, WeitzelJN. Genetic cancer risk assessment for breast cancer in Latin America. Rev Invest Clin. 2017;69(2):94–102. doi:10.24875/RIC.1700219528453507
   PubMedGoogle Scholar
• Cruz-CorreaM, Pérez-MayoralJ, DutilJ, et al. Clinical cancer genetics disparities among latinos. J Genet Couns. 2017;26(3):379–386. doi:10.1007/s10897-016-0051-x27957667
   PubMed Web of Science ®Google Scholar
• Chapman-DavisE, ZhouZN, FieldsJC, et al. Racial and ethnic disparities in genetic testing at a hereditary breast and ovarian cancer center. J Gen Intern Med. 2021;36(1):35–42. doi:10.1007/s11606-020-06064-x32720237
   PubMed Web of Science ®Google Scholar
• ChalelaP, PagánJA, SuD, MuñozE, RamirezAG. Breast cancer genetic testing awareness, attitudes and intentions of latinas living along the US-Mexico border: a Qualitative Study. J Community Med Health Educ. 2012;2. doi:10.4172/2161-0711.1000152
   Google Scholar
• BellaicheMMJ, FanW, WalbertHJ, et al. Disparity in access to oncology precision care: a geospatial analysis of driving distances to genetic counselors in the U.S. Front Oncol. 2021;11:689927. doi:10.3389/fonc.2021.68992734222017
   PubMed Web of Science ®Google Scholar
• GrantP, LangloisS, LyndLD, AustinJC, ElliottAM. Out-of-pocket and private pay in clinical genetic testing: a scoping review. Clin Genet. 2021;100(5):504–521. doi:10.1111/cge.1400634080181
   PubMed Web of Science ®Google Scholar
• ChuAT-W, TseDM-S, SuenDTK, KwongA. Baseline knowledge and receptiveness to genetic testing for hereditary breast and ovarian cancer syndromes in Chinese high-risk females. J Community Genet. 2021;12(3):431–438. doi:10.1007/s12687-021-00518-333928521
   PubMed Web of Science ®Google Scholar
• BlazerKR, Chavarri-GuerraY, Villarreal GarzaC, et al. Development and pilot implementation of the Genomic Risk Assessment for Cancer Implementation and Sustainment (GRACIAS) intervention in Mexico. JCO Glob Oncol. 2021;7(7):992–1002. doi:10.1200/GO.20.0058734181458
   PubMedGoogle Scholar
• KantarjianH, SteensmaD, Rius SanjuanJ, ElshaugA, LightD. High cancer drug prices in the United States: reasons and proposed solutions. J Oncol Pract. 2014;10(4):e208–e211. doi:10.1200/JOP.2013.00135124803662
   PubMedGoogle Scholar
• Villarreal-GarzaC. Abstract IA23: steps to address the profound disparity in access to genetic cancer risk assessment in Mexico: documenting hereditary breast and ovarian cancer and the beginning of a prevention program. In: Behavioral and Social Science. American Association for Cancer Research; 2015:IA23–IA23. doi:10.1158/1538-7755.DISP14-IA23
   Google Scholar
• Howard-AndersonJ, GanzPA, BowerJE, StantonAL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104(5):386–405. doi:10.1093/jnci/djr54122271773
   PubMedGoogle Scholar
• YfantisA, IntasG, ToliaM, et al. Health-related quality of life of young women with breast cancer. Review of the literature. J BUON. 2018;23(1):1–6.
   Web of Science ®Google Scholar
• HubbelingHG, RosenbergSM, González-RobledoMC, et al. Psychosocial needs of young breast cancer survivors in Mexico City, Mexico. Gripsrud BH, ed. PLoS One. 2018;13(5):e0197931. doi:10.1371/journal.pone.019793129787612
   PubMed Web of Science ®Google Scholar
• Villarreal‐GarzaC, López‐MartínezEA, Martínez‐CannonBA, et al. Medical and information needs among young women with breast cancer in Mexico. Eur J Cancer Care. 2019;28(4). doi:10.1111/ecc.13040
   Web of Science ®Google Scholar
• Villarreal-GarzaC, PlatasA, Martinez-CannonBA, et al. Information needs and internet use of breast cancer survivors in Mexico. Breast J. 2017;23(3):373–375. doi:10.1111/tbj.1274727943486
   PubMed Web of Science ®Google Scholar
• Villarreal-GarzaC, PlatasA, MiajaM, et al. Patients’ satisfaction with a supportive care program for young breast cancer patients in Mexico: Joven & Fuerte supports patients’ needs and eases their illness process. Support Care Cancer. 2020;28(10):4943–4951. doi:10.1007/s00520-020-05334-y32020358
   PubMed Web of Science ®Google Scholar